Showing results (171-180 of 343) with videos related to
Sort By:
Pageof 35
Oncotarget|June 4, 2015
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cellsMichele Dal Bo, Tiziana D'Agaro, Stefania Gobessi, et al.Blood|March 22, 2015
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cellsMaria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, et al.Carcinogenesis|January 22, 2014
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferationMichele Massimino, Maria Letizia Consoli, Maria Mesuraca, et al.Frontiers in Oncology|March 13, 2023
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseasesEnrico La Spina, Sebastiano Giallongo, Cesarina Giallongo, et al.European Journal of Haematology|March 4, 2021
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocolFortunato Morabito, Giovanni Tripepi, Ernesto Vigna, et al.Diseases (Basel, Switzerland)|February 26, 2026
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian CentersVittorio Del Fabro, Lara Gullo, Giuliana Giunta, et al.Biomarker Research|February 10, 2025
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemiaAnnalisa Chiarenza, Gaia Vertillo Aluisio, Nunziatina Laura Parrinello, et al.Cancer|September 2, 2023
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditionsAndrea Duminuco, Antonella Nardo, Alessandra Orofino, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 16, 2010
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cellsMatilde D'Asaro, Carmela La Mendola, Diana Di Liberto, et al.Ejhaem|July 26, 2026
Real-World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA SurveyFrancesca Fazio, Alfonso Piciocchi, Paolo de Fabritiis, et al.Pageof 35